Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Jacobus A. Burgers"'
Autor:
Floris Dammeijer, Cornedine J. De Gooijer, Mandy van Gulijk, Melanie Lukkes, Larissa Klaase, Lysanne A. Lievense, Cynthia Waasdorp, Merel Jebbink, Gerben P. Bootsma, Jos A. Stigt, Bonne Biesma, Margaretha E.H. Kaijen-Lambers, Joanne Mankor, Heleen Vroman, Robin Cornelissen, Paul Baas, Vincent Van der Noort, Jacobus A. Burgers, Joachim G. Aerts
Publikováno v:
EBioMedicine, Vol 64, Iss , Pp 103160- (2021)
Background: Gemcitabine is a frequently used chemotherapeutic agent but its effects on the immune system are incompletely understood. Recently, the randomized NVALT19-trial revealed that maintenance gemcitabine after first-line chemotherapy significa
Externí odkaz:
https://doaj.org/article/3c5ff16d06e342ff8c1730cb7bdef69d
Autor:
Job P. van Kooten, Cornedine J. de Gooijer, Jan H. von der Thüsen, Alexandra R.M. Brandt-Kerkhof, Arend G.J. Albers, Max J. Lahaye, Kim Monkhorst, Jacobus A. Burgers, Joachim G.J.V. Aerts, Cornelis Verhoef, Eva V.E. Madsen
Publikováno v:
European Journal of Surgical Oncology, 49(3), 611-618. W.B. Saunders
Background: Malignant peritoneal mesothelioma (MPM) is a rare and aggressive cancer that has a poor prognosis. An earlier population-based study found that the majority of Dutch patients do not receive anti-cancer treatment. In 2015, Dutch Malignant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ad10a8e4ebc73a5293909c98d080777
https://pure.eur.nl/en/publications/3566a678-18c9-4a57-a424-5192f03b9382
https://pure.eur.nl/en/publications/3566a678-18c9-4a57-a424-5192f03b9382
Autor:
Nikki de Rouw, René J. Boosman, Jacobus A. Burgers, Alwin D. R. Huitema, Anne-Marie C. Dingemans, Hieronymus. J. Derijks, David M. Burger, Berber Piet, Lizza E. L. Hendriks, Bonne Biesma, Melinda A. Pruis, Daphne W. Dumoulin, Sander Croes, Ron H. J. Mathijssen, Michel M. van den Heuvel, Rob ter Heine
Publikováno v:
Cancer Chemotherapy and Pharmacology, 91, 33-42
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer Verlag
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer-Verlag
Cancer Chemotherapy and Pharmacology, 91, 1, pp. 33-42
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer Verlag
Cancer Chemotherapy and Pharmacology, 91(1), 33-42. Springer-Verlag
Cancer Chemotherapy and Pharmacology, 91, 1, pp. 33-42
Item does not contain fulltext PURPOSE: Pemetrexed is a chemotherapeutic drug in the treatment of non-small cell lung cancer and mesothelioma. Optimized dosing of pemetrexed based on renal function instead of body surface area (BSA) is hypothesized t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f89d8fdab2aea47b4e702192ee6d7831
https://hdl.handle.net/2066/290955
https://hdl.handle.net/2066/290955
Autor:
Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, Michael Schenker, Bogdan Zurawski, Sang-We Kim, Mauricio Mahave, Aurelia Alexandru, Solange Peters, Adam Pluzanski, Reyes Bernabe Caro, Helena Linardou, Jacobus A. Burgers, Makoto Nishio, Alex Martinez-Marti, Koichi Azuma, Rita Axelrod, Luis G. Paz-Ares, Suresh S. Ramalingam, Hossein Borghaei, Kenneth J. O’Byrne, Li Li, Judith Bushong, Ravi G. Gupta, Diederik J. Grootendorst, Laura J. Eccles, Julie R. Brahmer
Publikováno v:
Journal of Thoracic Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74bfa2da3b17b9b98ecf986a2fa8bc01
https://doi.org/10.1016/j.jtho.2023.04.021
https://doi.org/10.1016/j.jtho.2023.04.021
Publikováno v:
British Journal of Clinical Pharmacology, 89, 699-704
British Journal of Clinical Pharmacology, 89, 2, pp. 699-704
British Journal of Clinical Pharmacology, 89, 2, pp. 699-704
Contains fulltext : 291213.pdf (Publisher’s version ) (Closed access) PURPOSE: Pemetrexed is a cytotoxic drug used for the treatment of lung cancer and mesothelioma. The use of a low test dosing of cytotoxic drugs may aid in dose individualization
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d72ee019ab33835b8e686f90c8cc4552
https://doi.org/10.1111/bcp.15520
https://doi.org/10.1111/bcp.15520
Autor:
René J. Boosman, Jacobus A. Burgers, Egbert F. Smit, Neeltje Steeghs, Anthonie J. van der Wekken, Jos H. Beijnen, Alwin D. R. Huitema, Rob ter Heine
Publikováno v:
Drugs, 82, 15-32
Drugs, 82, 1, pp. 15-32
Drugs, 82, 1, pp. 15-32
Contains fulltext : 249108.pdf (Publisher’s version ) (Closed access) In oncology, and especially in the treatment of non-small-cell lung cancer (NSCLC), dose optimization is often a neglected part of precision medicine. Many drugs are still being
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad38f56490b27a933bb6f8eabb9eafb3
https://doi.org/10.1007/s40265-021-01654-3
https://doi.org/10.1007/s40265-021-01654-3
Autor:
Kevin B. W. Groot Lipman, Cornedine J. de Gooijer, Thierry N. Boellaard, Ferdi van der Heijden, Regina G. H. Beets-Tan, Zuhir Bodalal, Stefano Trebeschi, Jacobus A. Burgers
Publikováno v:
European Radiology. Springer, Cham
Objectives In many countries, workers who developed asbestosis due to their occupation are eligible for government support. Based on the results of clinical examination, a team of pulmonologists determine the eligibility of patients to these programs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba5eb2199fa28b2e44841496ef5ac4c6
https://cris.maastrichtuniversity.nl/en/publications/c616aab3-784f-44c1-a9f3-3c5b37d0eced
https://cris.maastrichtuniversity.nl/en/publications/c616aab3-784f-44c1-a9f3-3c5b37d0eced
Publikováno v:
ERJ Open Research, Vol 4, Iss 4 (2018)
Systemic treatment is the standard treatment for unresectable stage III and IV lung cancer. Nevertheless, a 5–10% death rate has been described within 30 days after the last systemic treatment, suggesting that these patient did not benefit. We anal
Externí odkaz:
https://doaj.org/article/a3e8b5299e89455a997886fd85ec711e
Autor:
Jan de Boer, Charlotte L. Zuur, Vincent A. de Weger, Bastiaan Nuijen, Alfons J. M. Balm, Charlotte W Duinkerken, Lisette van der Molen, Serena Marchetti, Wouter A. Dreschler, Jacobus A. Burgers, Hilde Rosing, Dick Pluim, Jos H. Beijnen, Jan H.M. Schellens, Michael Hauptmann
Publikováno v:
Otology & neurotology, 42(5), 678-685. Lippincott Williams and Wilkins
Otology and Neurotology, 42(5), 678-685. LIPPINCOTT WILLIAMS & WILKINS
Otology and Neurotology, 42(5), 678-685. LIPPINCOTT WILLIAMS & WILKINS
Objectives: To determine safety, feasibility, and preliminary activity of transtympanic injection of sodium thiosulfate (STS) against cisplatin-induced hearing loss (CIHL). DESIGN Randomized controlled trial. SETTING Tertiary cancer hospital. PATIENT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::910a70514de9021b2f77459cf7b8ff70
https://doi.org/10.1097/mao.0000000000003069
https://doi.org/10.1097/mao.0000000000003069
Autor:
Nikki, de Rouw, René J, Boosman, Jacobus A, Burgers, Alwin D R, Huitema, Anne-Marie C, Dingemans, Hieronymus J, Derijks, David M, Burger, Berber, Piet, Lizza E L, Hendriks, Bonne, Biesma, Melinda A, Pruis, Daphne W, Dumoulin, Sander, Croes, Ron H J, Mathijssen, Michel M, van den Heuvel, Rob, Ter Heine
Publikováno v:
Cancer chemotherapy and pharmacology. 91(1)
Pemetrexed is a chemotherapeutic drug in the treatment of non-small cell lung cancer and mesothelioma. Optimized dosing of pemetrexed based on renal function instead of body surface area (BSA) is hypothesized to reduce pharmacokinetic variability in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::08f2e0666f49f6f685f3d626007f6077
https://pubmed.ncbi.nlm.nih.gov/36413252
https://pubmed.ncbi.nlm.nih.gov/36413252